Cargando…
P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429468/ http://dx.doi.org/10.1097/01.HS9.0000969472.42363.47 |
| _version_ | 1785090720683524096 |
|---|---|
| author | Skarbnik, Alan Kittai, Adam Miranda, Miguel Yong, Alan Roos, Jack Hettle, Robert Palazuelos-Munoz, Sarah Shetty, Vikram Ghia, Paolo |
| author_facet | Skarbnik, Alan Kittai, Adam Miranda, Miguel Yong, Alan Roos, Jack Hettle, Robert Palazuelos-Munoz, Sarah Shetty, Vikram Ghia, Paolo |
| author_sort | Skarbnik, Alan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429468 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104294682023-08-17 P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA Skarbnik, Alan Kittai, Adam Miranda, Miguel Yong, Alan Roos, Jack Hettle, Robert Palazuelos-Munoz, Sarah Shetty, Vikram Ghia, Paolo Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429468/ http://dx.doi.org/10.1097/01.HS9.0000969472.42363.47 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Skarbnik, Alan Kittai, Adam Miranda, Miguel Yong, Alan Roos, Jack Hettle, Robert Palazuelos-Munoz, Sarah Shetty, Vikram Ghia, Paolo P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA |
| title | P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_full | P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_fullStr | P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_full_unstemmed | P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_short | P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_sort | p642: a matching-adjusted indirect comparison of the efficacy and safety of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429468/ http://dx.doi.org/10.1097/01.HS9.0000969472.42363.47 |
| work_keys_str_mv | AT skarbnikalan p642amatchingadjustedindirectcomparisonoftheefficacyandsafetyofacalabrutinibversuszanubrutinibinrelapsedorrefractorychroniclymphocyticleukemia AT kittaiadam p642amatchingadjustedindirectcomparisonoftheefficacyandsafetyofacalabrutinibversuszanubrutinibinrelapsedorrefractorychroniclymphocyticleukemia AT mirandamiguel p642amatchingadjustedindirectcomparisonoftheefficacyandsafetyofacalabrutinibversuszanubrutinibinrelapsedorrefractorychroniclymphocyticleukemia AT yongalan p642amatchingadjustedindirectcomparisonoftheefficacyandsafetyofacalabrutinibversuszanubrutinibinrelapsedorrefractorychroniclymphocyticleukemia AT roosjack p642amatchingadjustedindirectcomparisonoftheefficacyandsafetyofacalabrutinibversuszanubrutinibinrelapsedorrefractorychroniclymphocyticleukemia AT hettlerobert p642amatchingadjustedindirectcomparisonoftheefficacyandsafetyofacalabrutinibversuszanubrutinibinrelapsedorrefractorychroniclymphocyticleukemia AT palazuelosmunozsarah p642amatchingadjustedindirectcomparisonoftheefficacyandsafetyofacalabrutinibversuszanubrutinibinrelapsedorrefractorychroniclymphocyticleukemia AT shettyvikram p642amatchingadjustedindirectcomparisonoftheefficacyandsafetyofacalabrutinibversuszanubrutinibinrelapsedorrefractorychroniclymphocyticleukemia AT ghiapaolo p642amatchingadjustedindirectcomparisonoftheefficacyandsafetyofacalabrutinibversuszanubrutinibinrelapsedorrefractorychroniclymphocyticleukemia |